Shield Therapeutics【STX】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

2.85

買値

2.80

売値

2.90

出来高

1,516,809

2.75 日の範囲 2.85

1.075 52 週間の範囲 7.65

時価総額

22.1M

前日終値

2.85

始値

2.75

時刻

60000

2.82

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

3,080,998

発行済株式数

775,429,360

配当利回り

PER

-0.66

1 株当たり利益 (EPS)

-0.04

歳入

13.09M

純利益

-33.29M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.shieldtherapeutics.com

本社

Newcastle Upon Tyne, Gbr

設立

Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker STX. The last closing price for Shield Therapeutics was 2.85p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 7.65p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £22.10 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.66.

Shield Therapeutics shares up on strong October sales

Shield Therapeutics PLC on Thursday said it remains on track to meet its full-year revenue covenant target following ...

Shield Therapeutics PLC Business Update

Shield Therapeutics PLC 21 November 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Business Update Recruitment completed of the Phase 3 confirmatory Study in...

Shield Therapeutics shares slide as it expands financing arrangement

Shield Therapeutics PLC on Tuesday said it has strengthened its financial foundation in the hope of becoming cash flo ...

Shield Therapeutics PLC Q3 Trading Update

Shield Therapeutics PLC 29 October 2024 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse...

Shield Therapeutics PLC Results from Phase 3 paediatric study

Shield Therapeutics PLC 25 September 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Results from Phase 3 paediatric study Pivotal Trial of ACCRUFeR®/FeRACCRU®...

Shield Therapeutics revenue triples, but cost rises widen annual loss

Shield Therapeutics PLC said on Wednesday that its revenue had multiplied threefold, but an increased cost of sales a ...

Shield Therapeutics PLC Interim results

Shield Therapeutics PLC 04 September 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Interim results for the six months ended 30 June 2024 More than threefold...

TRADING UPDATES: Shield Therapeutics lands Canada win; RUA revenue up

The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by A ...

Shield Therapeutics PLC ACCRUFeR® Approved by Health Canada

Shield Therapeutics PLC 27 August 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") ACCRUFeR® Approved by Health Canada ACCRUFeR® is the only oral iron therapy...

Shield Therapeutics PLC Notice of interim results

Shield Therapeutics PLC 14 August 2024 Shield Therapeutics plc ("Shield" or the "Company" or the "Group") Notice of interim results London, UK, 14 August 2024: Shield Therapeutics plc...